Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Apr 15, 2026; 18(4): 116365
Published online Apr 15, 2026. doi: 10.4251/wjgo.v18.i4.116365
Published online Apr 15, 2026. doi: 10.4251/wjgo.v18.i4.116365
Occult intestinal angiosarcoma presenting as refractory anemia during tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A case report
Tala Najdi, Samah Seif, Diana Khoury, Roland Eid, Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut 166830, Lebanon
Antony Kahwagi, Perla Wehbe, Rita Slim, Department of Gastroenterology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut 166830, Lebanon
Rita Karam, Department of Medical Imaging, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut 166830, Lebanon
Layal El Halabi, Department of Oncology, Lebanese Hospital Geitaoui, Beirut 1709, Lebanon
Ghassan Chakhtoura, Department of Digestive Surgery, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut 166830, Lebanon
Viviane Trak, Department of Pathology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut 166830, Lebanon
Author contributions: Najdi T, Seif S, Khoury D, Kahwagi A, and Wehbe P performed data collection and assembly; Najdi T, Eid R, Karam R, El Halabi L, Chakhtoura G, Slim R, and Trak V contributed to data analysis and interpretation; Najdi T and Eid R drafted the manuscript; all authors approved the final version of the manuscript.
Informed consent statement: Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.
Conflict-of-interest statement: All authors declare there is no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Tala Najdi, MD, Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Achrafieh, Beirut 166830, Lebanon. tala.najdi@net.usj.edu.lb
Received: November 14, 2025
Revised: December 5, 2025
Accepted: January 4, 2026
Published online: April 15, 2026
Processing time: 148 Days and 7.6 Hours
Revised: December 5, 2025
Accepted: January 4, 2026
Published online: April 15, 2026
Processing time: 148 Days and 7.6 Hours
Core Tip
Core Tip: Angiosarcoma is rare and carries a poor prognosis, often presenting subtly both clinically and radiologically. In some cases, it manifests only as persistent unexplained anemia, making its early recognition difficult. The tumor may remain hidden, mimicking benign lesions, with symptoms masked or altered by concurrent treatments. In patients receiving tyrosine kinase inhibitors, such as for chronic myeloid leukemia, modulation of the vascular endothelial growth factor pathway and related mechanisms can further obscure tumor behavior and distort imaging findings, contributing to diagnostic delay.